The US Food and Drug Administration (FDA) just published draft guidance to assist sponsors determine the appropriate supplement category for biosimilar applications and its goals for reviewing them.

UB classifies data into three risk-based categories to regulate access to, use of, and necessary precautions required to the protect university data. This policy provides a classification framework ...